,,iv #aah? ,,congress #b;d ,session ,h4 ,,res4 #acjg ,,9 ,,! ,,h\se ,,( ,,repres5tatives ,june #ah1 #bjbd,mrs4 ,d+ell 7= h]self & ,mr4 ,kelly ( ,p5nsylvania7 submitt$ ! foll[+ resolution2 :i* 0 ref]r$ to ! ,committee on ,en]gy & ,comm]ce ,,resolution ,express+ support = ! designation ( ,june #bj1 #bjbd1 z ,_w ,,f%d ,day4 ,:]eas facioscapulohum]al muscul> dy/rophy 7,,f%d7 is a g5etic neuromuscul> disease 7,,nmd7 t leads to ! weak5+ ( skeletal muscles2 ,:]eas ,,f%d's "n comes f ! typical patt]n ( muscle weakness at onset1 beg9n+ ) ! face 7facio71 %\ld] girdle 7scapulo71 & upp] arms 7hum]al72 ,:]eas ,,f%d ,type #a is ! m common =m ( ,,f%d1 acc\nt+ = approximately #ie p]c5t ( ,,f%d cases2 results f deletions 9 ! ,d#d,z#d region on *romosome #d2 & leads to abnormal expression ( ! ,,dux#d g5e2 ,:]eas1 approximately #e p]c5t ( ,,f%d cases1 kn[n z ,,f%d ,type #b1 are l9k$ to mutations on a g5e call$ ,,sm*d#a1 locat$ on *romosome #ah2 ,:]eas !re are /ill _m ,,f%d cases ( unkn[n g5etic cause2 ,:]eas ,,f%d is an inh]it$ condition t c affect _m family memb]s across g5]ations2 ,:]eas ,,f%d is g5etically transmissible 9 an autosomal dom9ant fa%ion1 mean+ t an affect$ p>5t has a #ej p]c5t *ance ( pass+ ! g5etic defect on to ea* *ild2 ,:]eas #cj p]c5t ( new ,,f%d pati5ts h no prior family hi/ory ( ! disease & are affect$ z a result ( cong5ital spontane\s g5etic mutation2 ,:]eas ,,f%d exi/s worldwide1 affects bo? sexes equally1 & has no p>ticul> racial1 geographic1 or e?nic di/ribution2 ,:]eas an e/imat$ #a 9 #h1jjj individuals1 or #da1dhg ,am]icans1 are liv+ ) ,,f%d2 ,:]eas ,,f%d symptoms c develop at any age & c diff] 9 ! initial patt]n ( muscle weakness2 ,:]eas weakness 9 abdom9al muscles is common & c lead to lordosis1 an exagg]at$ curve 9 ! l[] sp9e2 ,:]eas ! loss ( upp] body mobility is a debilitat+ symptom ( ,,f%d t significantly impacts pati5ts' ability to p]=m daily tasks necess>y to c>e = !mselves2 ,:]eas l[] leg weakness (t5 occurs & c lead to a condition call$ foot drop1 :]e ! foot /ays d[n aft] pu%+ (f :5 walk+2 ,:]eas ,,f%d c r$uce pati5ts' ability to "w & e>n a liv+2 ,:]eas asymmetrical muscle loss is a hallm>k symptom ( ,,f%d ) an unkn[n cause1 & mo/ pati5ts obs]ve t "o arm1 %\ld] blade1 or l[] leg is weak5$ :ile ! o!r rema9s /rong]2 ,:]eas ab\t #bj p]c5t ( ,,f%d pati5ts w become dep5d5t on a :eel*air or scoot]2 ,:]eas pati5ts ) ,,f%d may develop progressive weakness ( ! respiratory muscles or scoliosis1 :i* c cause fatal respiratory insuffici5cy2 ,:]eas m ?an #gj p]c5t ( ,,f%d pati5ts exp]i5ce debilitat+ pa9 & fatigue1 :i* c sev]ely limit daily activities2 ,:]eas ! loss ( facial expression & mobility1 z well z o!rs' lack ( und]/&+ ( ,,f%d1 is emotionally di/ress+ & c cause ,,f%d pati5ts to )draw socially2 ,:]eas individuals ) ,,f%d1 l ^? ) o!r r>e disord]s1 exp]i5ce *all5ges 9 obta9+ a diagnosis1 ) ! av]age "t to receive an accurate ,,f%d diagnosis be+ #i ye>s2 ,:]eas g5etic te/+ is ne$$ to def9itively diagnose ,,f%d1 & fur!r inve/m5ts 9 g5etic te/+ are requir$ to ensure access to te/+ = all ,am]icans2 ,:]eas1 to date1 ! ,food & ,drug ,adm9i/ration 7,,fda7 has yet to approve any treatm5ts = ,,f%d2 ,:]eas1 z a result ( ! ,orphan ,drug ,act1 !re h be5 important advances 9 rese>* on & treatm5t = r>e diseases1 includ+ ef=ts to develop treatm5ts = ,,f%d2 ,:]eas ,congress & ! ,,fda h affirm$ ! importance ( incorporat+ pati5t p]spectives ?r\gh\t ! drug review process ?r\gh implem5tation ( ! #ba/ ,c5tury ,cures ,act1 ! ,,he>t ,act1 & ,,fda guidance2 ,:]eas ! ,,fda's ,pati5t-,focus$ ,drug ,developm5t program is a critical res\rce t all[s pati5ts & c>egiv]s to educate ! ,,fda & o!r /akehold]s on _! liv$ exp]i5ces2 ,:]eas !re is a critical ne$ = rese>* & developm5t to advance treatm5ts = ,,f%d2 ,:]eas ! ,,f%d ,society1 a nonpr(it organization e/abli%$ 9 #aiia1 is d$icat$ to increas+1 engag+1 & emp[]+ /akehold]s & aggressively lev]ag+ & exp&+ res\rces1 ) ! goal ( develop+ treatm5ts = ,,f%d by #bjbe & ev5tually a cure2 ,:]eas1 on ,june #bi1 #bjbj1 ! ,,f%d community held its fir/-ev] ext]nally l$ pati5t-focus$ drug developm5t meet+2 & ,:]eas ,,f%d pati5t advocacy organizations1 rese>* fund+ nonpr(its1 bioph>maceutical indu/ry p>tn]s1 & o!r key /akehold]s sponsor ,_w ,,f%d ,day 9 ! ,unit$ ,/ates to increase public aw>5ess & g5]ate additional support = ,,f%d3 ,n[1 !re=e1 be x ,t ! ,h\se ( ,repres5tatives-- 7#a7 supports ! designation ( ,_w ,,f%d ,day2 & 7#b7 recognizes ! importance (-- 7,a7 improv+ aw>5ess ( & education ab\t facioscapulohum]al muscul> dy/rophy 79 ?is resolution ref]r$ to z ,,f%d72 7,b7 enc\rag+ accurate & e>ly diagnosis ( ,,f%d ?r\gh g5etic scre5+2 7,c7 support+ & fund+ future biom$ical & sci5tific rese>* to improve physical function+ & quality ( life = individuals liv+ ) ,,f%d2 7,d7 develop+ new treatm5ts1 diagno/ics1 & cures = ,,f%d2 & 7,e7 advanc+ programs & policies t support individuals liv+ ) ,,f%d & _! c>egiv]s4